Literature DB >> 24874843

Akt-mediated transforming growth factor-β1-induced epithelial-mesenchymal transition in cultured human esophageal squamous cancer cells.

X Xuan1, Q Zeng2, Y Li3, Y Gao3, F Wang3, H Zhang3, Z Wang3, H He3, S Li3.   

Abstract

Epithelial-mesenchymal transition (EMT) has a crucial role during embryonic development and has also come under intense scrutiny as a mechanism through which esophageal squamous cell cancer (ESCC) progresses to become metastatic. Transforming growth factor beta (TGF-β)-mediated EMT has been observed in a variety of cell types and has been identified as the main inducer of EMT in many types of cancer. Akt activity is involved in TGF-β-mediated EMT; however, its precise relationship and role in EMT in ESCC has not been well explained to date. Our data demonstrated that in human ESCC tissues Akt and its activated form, phosphorylated-Akt (p-Akt), were overexpressed; in addition, Akt and p-Akt were negatively correlated with epithelial cadherin (E-cadherin). In EC-9706 cells, exogenous TGF-β1 could induce EMT and at the same time could increase the EC-9706 cell invasive and metastatic ability. Moreover, Akt knockdown by small-interfering RNA could attenuate the EMT induced by TGF-β1 by increasing the epithelial marker E-cadherin and decreasing the mesenchymal marker Vimentin. Silencing Akt expression could decrease the migration ability of EC-9706 cells efficiently. In short, Akt is likely to have a more important role in the EMT induced by TGF-β1 in EC-9706 and may contribute to the invasive and metastatic ability of EC-9706. Akt may be an effective therapeutic in advanced and metastatic ESCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874843     DOI: 10.1038/cgt.2014.23

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  25 in total

1.  PI3K/Akt pathway mediates high glucose-induced lipogenesis and extracellular matrix accumulation in HKC cells through regulation of SREBP-1 and TGF-β1.

Authors:  Jun Hao; Shuxia Liu; Song Zhao; Qingjuan Liu; Xin Lv; Huan Chen; Yunyi Niu; Huijun Duan
Journal:  Histochem Cell Biol       Date:  2011-01-15       Impact factor: 4.304

2.  TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.

Authors:  Kati Räsänen; Antti Vaheri
Journal:  J Dermatol Sci       Date:  2010-03-17       Impact factor: 4.563

3.  Down-regulation of FXYD3 is induced by transforming growth factor-β signaling via ZEB1/δEF1 in human mammary epithelial cells.

Authors:  Hiroto Yamamoto; Ken-ichi Mukaisho; Hiroyuki Sugihara; Takanori Hattori; Shinji Asano
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

4.  Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.

Authors:  Masaki Shiota; Anousheh Zardan; Ario Takeuchi; Masafumi Kumano; Eliana Beraldi; Seiji Naito; Amina Zoubeidi; Martin E Gleave
Journal:  Cancer Res       Date:  2012-08-15       Impact factor: 12.701

5.  TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug.

Authors:  Eva Slabáková; Zuzana Pernicová; Eva Slavíčková; Andrea Staršíchová; Alois Kozubík; Karel Souček
Journal:  Prostate       Date:  2011-02-14       Impact factor: 4.104

Review 6.  Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression.

Authors:  Seth B Krantz; Mario A Shields; Surabhi Dangi-Garimella; Hidayatullah G Munshi; David J Bentrem
Journal:  J Surg Res       Date:  2011-10-08       Impact factor: 2.192

7.  [Effect of TGF-b1 siRNA-mediated silencing on Smad proteins in hepatic fibrosis rats].

Authors:  Yin-chun Sun; Qing Liang; Ke-li Qian; Lang Xiao; Qi Liu; Xiao-feng Shi
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2012-04

Review 8.  Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy.

Authors:  Aneel Bhangu; Gemma Wood; Alex Mirnezami; Ara Darzi; Paris Tekkis; Robert Goldin
Journal:  Surg Oncol       Date:  2012-09-14       Impact factor: 3.279

Review 9.  [Epithelial-mesenchymal transition in cancer progression].

Authors:  Monika Gos; Joanna Miłoszewska; Małgorzata Przybyszewska
Journal:  Postepy Biochem       Date:  2009

Review 10.  Smad anchor for receptor activation (SARA) in TGF-beta signaling.

Authors:  Wen-bin Tang; Guang-hui Ling; Lin Sun; Fu-You Liu
Journal:  Front Biosci (Elite Ed)       Date:  2010-06-01
View more
  5 in total

1.  CSN5 silencing inhibits invasion and arrests cell cycle progression in human colorectal cancer SW480 and LS174T cells in vitro.

Authors:  Gang Zhong; Huikai Li; Tao Shan; Nan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway.

Authors:  Zhang Ke; Sun Caiping; Zhang Qing; Wang Xiaojing
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

3.  Role of matrix metalloproteinase-9 in transforming growth factor-β1-induced epithelial-mesenchymal transition in esophageal squamous cell carcinoma.

Authors:  Xue Bai; Yun-Yun Li; Hong-Yan Zhang; Feng Wang; Hong-Liu He; Jin-Chao Yao; Ling Liu; Shan-Shan Li
Journal:  Onco Targets Ther       Date:  2017-06-02       Impact factor: 4.147

4.  Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism.

Authors:  Hai-Feng Zhang; Abdulraheem Alshareef; Chengsheng Wu; Shang Li; Ji-Wei Jiao; Hui-Hui Cao; Raymond Lai; Li-Yan Xu; En-Min Li
Journal:  Oncotarget       Date:  2015-10-06

5.  Human papillomavirus type 18 oncoproteins exert their oncogenicity in esophageal and tongue squamous cell carcinoma cell lines distinctly.

Authors:  Siaw Shi Boon; Zigui Chen; Jintao Li; Karen Y C Lee; Liuyang Cai; Rugang Zhong; Paul K S Chan
Journal:  BMC Cancer       Date:  2019-12-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.